-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, U1fxZwC3gCDiQ29Ndi17sLj4TjVynlkuFX5EXbjd65wSexC9gPQ2yxic9THMy3j+ TrGCbt/HXpdnXmUrU9fSbQ== 0000875320-08-000051.txt : 20080723 0000875320-08-000051.hdr.sgml : 20080723 20080723121003 ACCESSION NUMBER: 0000875320-08-000051 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080721 FILED AS OF DATE: 20080723 DATE AS OF CHANGE: 20080723 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graves Kurt CENTRAL INDEX KEY: 0001406337 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 08965145 BUSINESS ADDRESS: BUSINESS PHONE: 617-444-6100 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2008-07-21 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001406337 Graves Kurt C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2008-07-21 4 S 0 600 31.89 D 58974 D Common Stock 2008-07-21 4 S 0 2325 32.71 D 56649 D Transaction made pursuant to Mr. Graves' company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $32.71 (range $32.54 to $32.94). Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Valerie L. Andrews, Attorney-In-Fact 2008-07-23 -----END PRIVACY-ENHANCED MESSAGE-----